These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 10678789)
21. Symposium on antimicrobial therapy. VII. The fluoroquinolones. Greenfield RA J Okla State Med Assoc; 1993 Apr; 86(4):166-74. PubMed ID: 8387106 [TBL] [Abstract][Full Text] [Related]
22. Fluoroquinolones in animal health. Brown SA J Vet Pharmacol Ther; 1996 Feb; 19(1):1-14. PubMed ID: 8992019 [TBL] [Abstract][Full Text] [Related]
23. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Wagenlehner FM; Naber KG Clin Microbiol Infect; 2006 May; 12 Suppl 3():67-80. PubMed ID: 16669930 [TBL] [Abstract][Full Text] [Related]
24. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia. Foster MT Pharmacotherapy; 1993; 13(2 Pt 2):45S-50S. PubMed ID: 8474938 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. Oliveira AD; D'Azevedo PA; Francisco W Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812 [TBL] [Abstract][Full Text] [Related]
26. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity. Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869 [TBL] [Abstract][Full Text] [Related]
27. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Naber KG Int J Antimicrob Agents; 2001 Apr; 17(4):331-41. PubMed ID: 11295418 [TBL] [Abstract][Full Text] [Related]
29. Bacterial resistance to fluoroquinolones: lessons to be learned. Ball P Infection; 1994; 22 Suppl 2():S140-7. PubMed ID: 7927833 [TBL] [Abstract][Full Text] [Related]
30. Potential role of fluoroquinolones in the treatment of bacterial meningitis. Modai J Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):291-5. PubMed ID: 1864289 [TBL] [Abstract][Full Text] [Related]
31. Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW; Acar JF Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361 [TBL] [Abstract][Full Text] [Related]
32. Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. Bayer AS Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1102-10. PubMed ID: 2695331 [TBL] [Abstract][Full Text] [Related]
34. Is more than one quinolone needed in clinical practice? Paladino JA Ann Pharmacother; 2001 Sep; 35(9):1085-95. PubMed ID: 11573860 [TBL] [Abstract][Full Text] [Related]
35. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method. Janknegt R Pharmacoeconomics; 1994 Jul; 6(1):15-33. PubMed ID: 10147351 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate]. Minami S; Hattori R; Matsuda A Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):161-78. PubMed ID: 12890902 [TBL] [Abstract][Full Text] [Related]
37. Ciprofloxacin in multi-resistant infections in childhood: an audit. Khan DM; Bhutta ZA J Pak Med Assoc; 1995 Jun; 45(6):147-50. PubMed ID: 7474287 [TBL] [Abstract][Full Text] [Related]
38. Quinolones in perspective. Neu HC J Antimicrob Chemother; 1990 Oct; 26 Suppl B():1-6. PubMed ID: 2258336 [TBL] [Abstract][Full Text] [Related]